Cardiovascular pharmacotherapeutic considerations during pregnancy and lactation

Cardiology in Review

Volumn 12, Issue 5, 2004, Pages 240-261

  Qasqas, Shadi A ^a   McPherson, Camille ^b   Frishman, William H ^c,e   Elkayam, Uri ^d  

^a BARNES JEWISH HOSPITAL   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c WESTCHESTER MEDICAL CENTER   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; CARBONATE DEHYDRATASE INHIBITOR; CLOFIBRATE; CLONIDINE; COLESEVELAM; COLESTIPOL; DIAZOXIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EZETIMIBE; FENOFIBRATE; FIBRINOLYTIC AGENT; FUROSEMIDE; GEMFIBROZIL; HYDRALAZINE; LABETALOL; LOW MOLECULAR WEIGHT HEPARIN; METHYLDOPA; MINOXIDIL; NICOTINIC ACID; NIFEDIPINE; NITROPRUSSIDE SODIUM; UNINDEXED DRUG; WARFARIN;

ACIDEMIA; ANTIHYPERTENSIVE ACTIVITY; ANURIA; BASAL METABOLIC RATE; BLOOD DYSCRASIA; BLOOD PRESSURE REGULATION; BRADYCARDIA; BREAST FEEDING; CARDIOVASCULAR DISEASE; CESAREAN SECTION; CHOLESTEROL BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG EFFECT; FATIGUE; FEMALE; FETOTOXICITY; FETUS HEART RATE; FEVER; FLUSHING; HEADACHE; HEART OUTPUT; HEART PALPITATION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOTENSION; HYPOXIA; LACTATION; LUNG HYPOPLASIA; LUPUS ERYTHEMATOSUS; NEPHROTOXICITY; NEWBORN DEATH; NOSE CONGESTION; OLIGOHYDRAMNIOS; PLASMA RENIN ACTIVITY; PREGNANCY; PROTEINURIA; RASH; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESPIRATORY DISTRESS; REVIEW; RISK BENEFIT ANALYSIS; SACCHAROMYCES; SIDE EFFECT; SLEEP DISORDER; SODIUM RETENTION; SOLUTIO PLACENTAE; TACHYCARDIA; THROMBOCYTOPENIA; THYROTOXICOSIS; UTERUS BLOOD FLOW; VASCULAR RESISTANCE; VOMITING; WATER RETENTION;

ANTICHOLESTEREMIC AGENTS; ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; LACTATION; MATERNAL WELFARE; PLATELET AGGREGATION INHIBITORS; PREGNANCY;

EID: 4344583233     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.crd.0000102421.89332.43     Document Type: Review

References (127)

1. Report of the National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy. Am J Obstet Gynecol. 2000;183:S1-S22.
2. Lenfant C. Management of hypertension in pregnancy. J Clin Hypertens. 2001;3:71-72.
3. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003;289:2560-2572.
4. Awad K, Ali P, Frishman WH, et al. Pharmacologic approaches for the management of systemic hypertension in pregnancy. Heart Dis. 2000;2:124-132.
5. Brown MA, Hague WM, Higgins J, et al. The detection, investigation and management of hypertension in pregnancy: executive summary. Consensus statement from the Australasian Society for the Study of Hypertension in Pregnancy. Aust N ZJ Obstet Gynaecol. 2000;40:133-138.
6. Rey E, LeLorier J, Burgess E, et al. Report of the Canadian Hypertension Society consensus conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy. CMAJ. 1997;157:1245-1254.
7. Koch-Weser J. Drug therapy: hydralazine. N Engl J Med. 1976;295:320-323.
8. Pritchard JA, Pritchard SA. Standardized treatment of 154 consecutive cases of eclampsia. Am J Obstet Gynecol. 1975;123:543-552.
9. Ring G, Krames E, Shnider S, et al. Comparison of nitroprusside and hydralazine in hypertensive pregnant ewes. Obstet Gynecol. 1977;50:598-602.
10. Ladner CN, Weston PV, Brinkman CR III, et al. Effects ofhydralazine on utero-placental and fetal circulations. Am J Obstet Gynecol. 1970;108:375-381.
11. Jouppila P, Kirkinen P, Koivula A. Effect of antihypertensive drugs on placental and fetal blood flow. In: Kurjak A, Kossoff G, eds. Recent Advances in Ultrasound Diagnosis. Amsterdam: Elsevier Science Publishers; 1984:68-74.
12. Lunell NO, Lewander R, Nylund L, et al. Acute effect of dihydralazine on utero-placental blood flow in hypertension during pregnancy. Gynecol Obstet Invest. 1983;16:274-282.
13. Suonio S, Saarikoski S, Tahvanainen K, et al. Acute effects of dihydralazine mesylate, furosemide, and metoprolol on maternal hemodynamics in pregnancy-induced hypertension. Am J Obstet Gynecol. 1986;155:122-125.
14. Vink GS, Moodley J, Philpott RH. Effects of dihydralazine on the fetus in the treatment of maternal hypertension. Obstet Gynecol. 1970;50:519-522.
15. Spinnato J, Sibai BM, Anderson GD. Fetal distress after hydralazine therapy for severe pregnancy-induced hypertension. South Med J. 1986;79:559-562.
16. Kuzniar J, Skret A, Piela A, et al. Hemodynamic effects of intravenous hydralazine in pregnant women with severe hypertension. Obstet Gynecol. 1985;66:453-458.
17. Naden RP, Redman CW. Antihypertensive drugs in pregnancy. Clin Perinatol. 1985;12:521-538.
18. Liedholm H, Wahlin-Boll E, Hanson A, et al. Transplacental passage and breast milk concentrations of hydralazine. Eur J Clin Pharmacol. 1982;21:417-419.
19. Sankar D, Moodley J. Low-dose diazoxide in the emergency management of severe hypertension in pregnancy. S Afr Med J. 1984;65:279-280.
20. Dudley KDL. Minibolus diazoxide in the management of severe hypertension in pregnancy. Am J Obstet Gynecol. 1985;151:196-200.
21. Neuman J, Weiss B, Rabello Y, et al. Diazoxide for the acute control of severe hypertension complication pregnancy: a pilot study. Obstet Gynecol. 1979;53:50s-55s.
22. Schrefer J, Nissen D, eds. Mosby's GenRx, 11th ed. St. Louis: Mosby, Inc; 2001.
23. Michael CA. Use of labetalol in the treatment of severe hypertension during pregnancy. Br J Clin Pharmacol. 1979;8(suppl 2):211S-215S.
24. Lamming GD, Symonds EB. Use of labetalol and methyldopa in pregnancy induced hypertension. Br J Clin Pharmacol. 1979;8(suppl 2):217S-222S.
25. Hurst AK, Hoffman K, Frishman WH. The use of β-adrenergic blocking agents in pregnancy and lactation. In: Elkayam U, Gleicher N, eds. Cardiac Problems in Pregnancy, 3rd ed. New York: Wiley-Liss, Inc; 1998:357-369.
26. MacPherson M, Pipkin FB, Rutter N. The effect of maternal labetalol on the newborn infant. Br J Obstet Gynaecol. 1986;93:539-542.
27. Pickles CJ, Pipkin FB, Symonds EM. A randomized placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension. Br J Obstet Gynaecol. 1992;99:964-968.
28. Olsen KS, Beier-Holgersen R. Fetal death following labetalol administration in preeclampsia. Acta Obstet Gynecol Scand. 1992;71:145-147.
29. Haraldsson A, Geven W. Severe adverse effects of maternal labetalol in a premature infant. Acta Paediatr Scand. 1989;78:956-958.
30. Crooks BN, Deshpande SA, Hall C, et al. Adverse neonatal effects of maternal labetalol treatment. Arch Dis Child Fetal Neonatal Ed. 1998;79:F150-151.
31. Klarr JM, Bhatt-Mehta V, Donn SM. Neonatal adrenergic blockade following single dose maternal labetalol administration. Am J Perinatol. 1994;11:91-93.
32. Bowman ML, Bergmann M, Smith JF. Intrapartum labetalol for the treatment of maternal and fetal thyrotoxicosis. Thyroid. 1998;8:795-796.
33. el-Qarmalawi AM, Morsy AH, al-Fadly A, et al. Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension. Int J Gynaecol Obstet. 1995;49:125-130.
34. Walker JJ, Greer I, Calder AA. Treatment of acute pregnancy-related hypertension: labetalol and hydralazine compared. Postgrad Med J. 1983;59(suppl 3):168-170.
35. Lunell N, Kulas J, Rane A. Transfer of labetalol into amniotic fluid and breast milk in lactating women. Eur J Clin Pharmacol. 1985;28:597-599.
36. Willoughby JS. Sodium nitroprusside, pregnancy, and multiple intracranial aneurysms. Anaesth Intensive Care. 1984;12:351-357.
37. Paull J. Clinical report of the use of sodium nitroprusside in severe preeclampsia. Anaesth Intensive Care. 1975;3:72.
38. Stempel JE, O'Grady JP, Morton MJ, et al. Use of sodium nitroprusside in complications of gestational hypertension. Obstet Gynecol. 1982;60:533-538.
39. Ellis SC, Wheeler AS, James FM III, et al. Fetal and maternal effects of sodium nitroprusside used to counteract hypertension in gravid ewes. Am J Obstet Gynecol. 1982;143:766-770.
40. Lieb SM, Zugaib M, Nuwayhid B, et al. Nitroprusside induced hemodynamic alteration in normotensive and hypertensive pregnant sheep. Am J Obstet Gynecol. 1982;139:925-931.
41. Naulty J, Cefalo RC, Lewis PE. Fetal toxicity of nitroprusside in the pregnant ewe. Am J Obstet Gynecol. 1981;139:708-711.
42. Wheeler AS, James FM, Greiss FC, et al. Effects of nitroglycerin to control severe hypertension of pregnancy during cesarean section [Abstract]. Anesthesiology. 1979;51:563.
43. Shoemaker CT, Meyers M. Sodium nitroprusside for control of severe hypertensive disease of pregnancy: a case report and discussion of potential toxicity. Am J Obstet Gynecol. 1984;149:171-173.
44. Hood DD, Dewan DM, James FM, et al. The use of nitroglycerin in preventing the hypertensive response to tracheal intubation in severe preeclamptics. Anesthesiology. 1985;63:329-332.
45. Peng ATC, Gorman RS, Shulman SM, et al. Intravenous nitroglycerin for uterine relaxation in the post partum patient with retained placenta. Anesthesiology. 1989;71:172-173.
46. Fasseas P, Dharia N. Acute myocardial infarction in pregnancy. Cardiol Rev. 1998;15:23.
47. Calvin SE. Use of vasodilators during pregnancy. In: Elkayam U, Gleicher N, eds. Cardiac Problems in Pregnancy, 3rd ed. New York: Wiley-Liss Inc; 1998:391-397.
48. O'Grady JP, Parker RK, Patel SS. Nitroglycerin for rapid tocolysis: development of a protocol and a literature review. J Perinatol. 2000;20:27-33.
49. Cotton DB, Longmire S, Jones MM, et al. Cardiovascular alterations in severe pregnancy-induced hypertension: effects of intravenous nitroglycerin coupled with blood volume expansion. Am J Obstet Gynecol. 1986;154:1053-1059.
50. DeRosayro M, Nahrwold ML, Hill AB, et al. Nitroglycerin: plasma levels and effects in pregnant ewes [Abstract]. Anesthesiology. 1979;51:S312.
51. Valdivieso A, Valdes G, Spiro TE. Minoxidil in breast milk. Ann Intern Med. 1985;102:135.
52. American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics. 1994;93:137-150.
53. von Dadelszen P, Ornstein MP, Bull SB, et al. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet. 2000;355:87-92.
54. Mulrow CD, Chiquette E, Ferrer RL, et al. Management of Chronic Hypertension During Pregnancy: Evidence Report/Technology Assessment No. 14. AHRQ Publication No. 00-E011. Rockville, MD: Agency for Healthcare Research and Quality; August 2000.
55. de Swiet M. Maternal blood pressure and birthweight. Lancet. 2000;355:81-82.
56. Magee LA, Ornstein MP, von Dadelszen P. Management of hypertension in pregnancy. BMJ. 1999;318:1332-1336.
57. Horvath JS, Phippard A, Korda A, et al. Clonidine hydrochloride - a safe and effective antihypertensive agent in pregnancy. Obstet Gynecol. 1985;66:634-638.
58. Pipkin FB, Turner SR, Symonds EM. Possible risk with captopril during pregnancy: some animal data. Lancet. 1980;2:1256.
59. Broughton-Pipkin F, Symonds EM, Turner SR. The effect of captopril (SQ 14, 225) upon mother and fetus in the chronically cannulated ewe and in the pregnant rabbit. J Physiol. 1982;323:415-422.
60. Ferris TF, Weir EK. Effect of captopril on uterine blood flow and prostaglandin E synthesis in the pregnant rabbit. J Clin Invest. 1982;71:809-815.
61. Keith IM, Will JA, Weir EK. Captopril: association with fetal death and pulmonary vascular changes in the rabbit (41446). Proc Soc Exp Biol Med. 1982;170:378-383.
62. Broughton-Pipkin F, Wallace CP. The effect of enalapril (MK-421), an angiotensin-converting enzyme inhibitor, on the conscious pregnant ewe and her foetus. Br J Pharmacol. 1986;87:533-542.
63. Minsker DH, Bagdon WJ, MacDonald JS, et al. Maternotoxicity and fetotoxicity of an angiotensin-converting enzyme inhibitor, enalapril, in rabbits. Fund Appl Toxicol. 1990;14:461-470.
64. Binder N, Faber JJ. Effects of captopril on blood pressure, placental blood flow and uterine oxygen consumption in the pregnant rabbits. J Pharmacol Exp Ther. 1992;260:294-299.
65. Broughton-Pipkin F, Baker PN, Symoonds EM. Angiotensin-converting enzyme inhibitors in pregnancy. Lancet. 1989;2:96-97.
66. Schubiger G, Flury G, Nussberger J. Enalapril for pregnancy-induced hypertension: acute renal failure in a neonate. Ann Intern Med. 1988;108:215-216.
67. Duminy PC, Burger PD. Fetal abnormalities associated with the use of captopril during pregnancy [Letter]. S Afr Med J. 1982;60:805.
68. Guignard JP, Burgener F, Calame A. Persistent anuria in neonate: a side effect of captopril. Int J Pediatr Nephrol. 1981;2:133.
69. Thorpe-Beeston JG, Armar NA, Dancy M, et al. Pregnancy and ACE inhibitors. Br J Obstet Gynaecol. 1993;100:692-693.
70. Kreft-Jais C, Plouin PF, Tchoboutsky C, et al. Angiotensin-converting enzyme inhibitors during pregnancy: a survey of 22 patients given captopril and nine given enalapril. Br J Obstet Gynaecol. 1988;95:420-422.
71. Fiocchi R, Lijnen P, Fagard R, et al. Captopril during pregnancy. Lancet. 1984;2:1153.
72. Lindheimer MD, Katz A. Hypertension in pregnancy. N Engl J Med. 1985;313:675-680.
73. Barr M, Cohen MM. ACE inhibitor fetopathy and hypocalvaria: the kidney-skull connection. Teratology. 1991;44:485-495.
74. Hanssens M, Keirse M, Vankelecom F, et al. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynecol. 1991;78:128-135.
75. Easterling TR, Carr DB, Davis C, et al. Low-dose, short-acting, angiotensin-converting enzyme inhibitors as rescue therapy in pregnancy. Obstet Gynecol. 2000;96:956-961.
76. Nightingale SL. Warning on the use of ACE inhibitors in second and third trimester of pregnancy. JAMA. 1992;267:2445.
77. Lip GYH, Churchill D, Beevers M, et al. Angiotensin-converting-enzyme inhibitors in early pregnancy. Lancet. 1997;350:1446-1447.
78. Centers for Disease Control and Prevention. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy-United States, Canada, and Israel, 1987-1995. JAMA. 1997;277:1193-1194.
79. Shotan A, Widerhom J, Hurst A, et al. Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med. 1994;96:451-456.
80. Cozaar (Losartan potassium tablets) drug insert. West Point, PA: Merck & Co, Inc; 1995.
81. Saji H, Yamanaka M, Hagieara A, et al. Losartan and fetal toxic effects. Lancet. 2001;357:363.
82. Angiotensin-II-receptor inhibitors in pregnancy [Letter]. Lancet. 2001;357:1619.
83. Lambot MA, Vermeylen D, Noel JC. Angiotensin II receptor inhibitors in pregnancy. Lancet. 2001;357:1619-1620.
84. Chung NA, Lip GY, Beevers M, et al. Angiotensin II receptor inhibitors in pregnancy. Lancet. 2001;357:1620-1621.
85. Cohen E, Garry M. Diuretics in pregnancy. In: Elkayam U, Gleicher N, eds. Cardiac Problems in Pregnancy, 3rd ed. New York: Wiley-Liss Inc; 1998:351-356.
86. Drug Information for the Health Care Professional, vol I, 16th ed. Rockville MD, United States Pharmacopeial Convention; 1996.
87. Votta RA, Parada OH, Winograd RH, et al. Furosemide action on the creatinine concentration of amniotic fluid. Am J Obstet. 1975;123:621-624.
88. Briggs GG, Freeman RK, Yaffe SJ, eds. Drugs in Pregnancy and Lactation. A Reference Guide to Fetal and Neonatal Risk, 5th ed. Baltimore: Williams & Wilkins; 1998:765.
89. Merlob P, Litwin A, Mor N. Possible association between acetazolamide administration during pregnancy and metabolic disorders in the newborn. Eur J Obstet Gynecol Reprod Biol. 1990;35:85.
90. Worsham F, Beckman EN, Mitchell EH. Sacrococcygeal teratoma in a neonate. Association with maternal use of acetazolamide. JAMA. 1978;240:251-252.
91. Devoe LD, O'Dell BE, Castillo RA, et al. Metastatic pheochromocytoma in pregnancy and fetal biophysical assessment after maternal administration of alpha-adrenergic, beta-adrenergic, and dopamine antagonist. Obstet Gynecol, 1986;68(suppl):15s-18s.
92. Rubin PC, Butters L, Low RA, et al. Clinical pharmacological studies with prazosin during pregnancy complicated by hypertension. Br J Clin Pharmacol. 1983;16:543-547.
93. Manson JM, Freyssinges C, Ducrocq MB, et al. Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. Reprod Toxicol. 1996;10:439-446.
94. Henck JW, Craft WR, Black A, et al. Pre- and postnatal toxicity of the HMG-CoA reductase inhibitor atorvastatin in rats. Toxicol Sci. 1998;41:88-99.
95. Cox JL. Lipid-lowering drugs in pregnancy and lactation. In: Elkayam U, Gleicher N, eds. Cardiac Problems in Pregnancy, 3rd ed. New York: Wiley-Liss Inc; 1998:445-449.
96. Innis SM. Effect of cholestyramine administration during pregnancy in the rat. Am J Obstet Gynecol. 1983;146:13-16.
97. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation. 2002;106:1343-1421.
98. Committee of Principal Investigators. WHO Cooperative Trial on Primary Prevention of Ischemic Heart Disease with Clofibrate to Lower Serum Cholesterol: Final Mortality Follow-Up. Lancet. 1984;2:600.
99. Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med. 1980;68:122-140.
100. Ginsberg JS, Hirsh J, Turner DC, et al. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost. 1989;61:197-203.
101. Dahlman T, Hellgren MSC, Blomback M. Thrombosis prophylaxis in pregnancy with use of subcutaneous heparin adjusted by monitoring heparin concentration in plasma. Am J Obstet Gynecol. 1989;161:420-425.
102. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest. 2001;119:122s-31s.
103. Forestier F, Daffos F, Rainaut M, et al. Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy. Thromb Haemost. 1987;57:234.
104. Andrew M, Boneu B, Cade J, et al. Placental transport of low molecular weight heparin in the pregnant sheep. Br J Haematol. 1985;59:103-108.
105. Bar J, Cohen-Sacher B, Hod M, et al. Low-molecular-weight heparin for thrombophilia in pregnant women. Int J Gynaecol Obstet. 2000;69:209-213.
106. Sorensen HT, Johnsen SP, Larsen H, et al. Birth outcomes in pregnant women treated with low-molecular-weight heparin. Acta Obstet Gynecol Scand. 2000;79:655-659.
107. Casele HL, Laifer SA. Prospective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium. J Matern Fetal Neonatal Med. 2000;9:122-125.
108. Pettifor JM, Benson R. Congenital malformations associated with the administration of oral anticoagulants during pregnancy. J Pediatr. 1975;86:459-462.
109. Vitale N, De Feo M, De Santo LS, et al. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol. 1999;33:1637-1641.
110. Howe AM, Lipson AH, de Silva M, et al. Severe cervical dysplasia and nasal cartilage calcification following prenatal warfarin exposure. Am J Med Genet. 1997;71:391-396.
111. Haushka PV, Reid ML, Lian JB. Probable vitamin K dependence of gamma-carboxyglutamate formation in bone. Fed Proc. 1976;35:1354.
112. Iturbe-Alessio I, Fonseca M, Mutchinik O, et al. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Eng J Med. 1986;315:1390-1393.
113. Sherman S, Hall BD. Warfarin and fetal abnormality. Lancet. 1976;1:692.
114. Holzgreve W, Carey JC, Hall BD. Warfarin-induced fetal abnormalities. Lancet. 1976;2:914-915.
115. OlthofE, De Vries TW, Touwen BC, et al. Late neurological, cognitive and behavioral, sequelae of prenatal exposure to coumarins: a pilot study. Early Hum Dev. 1994;38:97-109.
116. Clark SL, Porter TF, West FG. Coumarin derivatives and breastfeeding. Obstet Gynecol. 2000;95:938-940.
117. Meschengieser SS, Fondevila CG, Santarelli MT, et al. Anticoagulation in pregnant women with mechanical heart valve prostheses. Heart. 1999;82:23-26.
118. Sbarouni E, Oakley CM. Outcome of pregnancy in women with valve prostheses. Br Heart J. 1994;71:196-201.
119. Salazar E, Izaguirre R, Verdejo J, et al. Failure of adjusted doses of sub-cutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prosthesis. J Am Coll Cardiol. 1996;27:1698-1703.
120. McGehee W. Anticoagulation in pregnancy. In: Elkayam U, Gleicher N, eds. Cardiac Problems in Pregnancy, 3rd ed. New York: Wiley-Liss, Inc; 1998:407-417.
121. Chan WS. What is the optimal management of pregnant women with valvular heart disease in pregnancy? Haemostasis. 1999;29(suppl S1): 105-106.
122. Turpie AGG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo after heart valve replacement. N Engl J Med. 1993;329:524-529.
123. Imperiale TF, Stollenwerk PA. A meta-analysis of low-dose aspirin for the prevention of pregnancy-induced hypertensive disease. JAMA. 1991;266:260-264.
124. CLASP Collaborative Group. CLASP: a randomised trial of low dose aspirin for the prevention and treatment of pre-eclampsia among 9,364 pregnant women (CLASP: Collaborative Low Dose Aspirin Study in Pregnancy). Lancet. 1994;343:619-629.
125. Duley L, Henderson-Smart D, Knight M, et al. Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. BMJ. 2001;322:329-333.
126. Baudo F. Emergency treatment with recombinant tissue plasminogen activator of pulmonary embolism in a pregnant woman with AT III deficiency. Am J Obstet Gynecol. 1990;163:1274-1275.
127. Flossdorf T, Breulmann M, Hopf HB. Successful treatment of massive pulmonary embolism with recombinant tissue plasminogen activator in a pregnant woman with intact gravidity and preterm labour. Intensive Care Med. 1990;16:454-456.